XONVEA 20 mg/20 mg, modified-release tablet 20 tablets
Active ingredients: Pyridoxine hydrochloride, Doxylamine succinate
Commercialized according to BDPMDispensing in France: Prescription only
Modified-release tablet20 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XONVEA 20 mg/20 mg, comprimé à libération modifiée
- Pharmaceutical form
- comprimé à libération modifiée
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 20 comprimé(s)
- Marketing authorisation holder
- EXELTIS SANTE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 27 Sept 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66800021CIP73027349CIP133400930273494Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| HYDROGÉNOSUCCINATE DE DOXYLAMINEcomprimé | 20 mg · un comprmé | SA |
| CHLORHYDRATE DE PYRIDOXINEcomprimé | 20 mg · un comprmé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.